1402042-27-6Relevant articles and documents
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability
Pati, Maria Laura,Vitale, Paola,Ferorelli, Savina,Iaselli, Mariaclara,Miciaccia, Morena,Boccarelli, Angelina,Di Mauro, Giuseppe Davide,Fortuna, Cosimo G.,Souza Domingos, Thaisa Francielle,Rodrigues Pereira da Silva, Luiz Cláudio,de Pádula, Marcelo,Cabral, Lucio Mendes,Sathler, Plínio Cunha,Vacca, Angelo,Scilimati, Antonio,Perrone, Maria Grazia
, p. 59 - 76 (2019/01/04)
A set of novel diarylisoxazoles has been projected using mofezolac (1) as a lead compound to investigate structure-inhibitory activity relationships of new compounds and the cyclooxygenases (COXs) catalytic activity. Mofezolac was chosen because is the mo
Pd(0)-catalyzed decarboxylative coupling and tandem C-H arylation/decarboxylation for the synthesis of heteroaromatic biaryls
Nandi, Debkumar,Jhou, Yang-Ming,Lee, Jhen-Yi,Kuo, Bing-Chiuan,Liu, Chien-Yu,Huang, Pei-Wen,Lee, Hon Man
, p. 9384 - 9390 (2013/01/15)
An effective Pd(0) carbene complex was successfully employed in the decarboxylative coupling of the heteroaromatic carboxylic acids (imidazo[1,2-a]pyridine and isoxazole) with aryl halides. For carboxyindoles, either decarboxylative coupling or tandem C-H arylation and decarboxylation occurred, leading to the formation of C2-monoarylated indoles.